(Q24244300)

29 October 2023

3

M Paul

M

Paul

1 reference

29 October 2023

D Shefet

1

D

Shefet

1 reference

15846713

29 October 2023

E Robenshtok

series ordinal

2

author given names

E

author last names

Robenshtock

1 reference

15846713

Cochrane Database of Systematic Reviews

29 October 2023

language of work or name

1 reference

20 April 2005

0 references

published in

0 references

cites work

Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home-acquired lower respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

Sparfloxacin for the treatment of community-acquired pneumonia: a pooled data analysis of two studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

Prospective randomized controlled study of ciprofloxacin versus imipenem-cilastatin in severe clinical infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Evaluation of roxithromycin (RU-965) versus cephradine in pneumococcal pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Randomized, double-blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Azithromycin versus comparative therapy for the treatment of community acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Prospective study of lower respiratory tract infections in an extended-care nursing home program: potential role of oral ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

[Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

A prediction rule to identify low-risk patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults. Sparfloxacin European Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Comparison of pefloxacin with ceftazidime in severe bronchopulmonary infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

[Comparative study of the effectiveness of enoxacin and amoxicillin in bacterial pneumonia by a double blind method]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

[Comparison of DL-8280 and amoxicillin in the treatment of respiratory tract infections]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004418.PUB2

7 January 2021

10.1002/14651858.CD004418.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_ekqnzkfugjgvrikqmk6cvovgdu

0 references